Neoanti­gen pi­o­neer Neon Ther­a­peu­tics casts off in search of $115M IPO to fu­el the race to a per­son­al­ized can­cer treat­ment

Can a be­spoke can­cer vac­cine ac­tu­al­ly suc­ceed in treat­ing in­di­vid­ual on­col­o­gy cas­es?

Neon Ther­a­peu­tics launched three years ago, set­ting out on a mis­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER